Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration (FDA) raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer (NSCLC) adenocarcinoma. The company stated that the FDA's written response to its Type C meeting request offers a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population. Emerging data suggest LP-300 may provide differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure in this subgroup.
The HARMONIC trial is investigating LP-300, a cisplatin/ethacraplatin analog, in never-smoker patients with relapsed advanced lung adenocarcinoma after tyrosine kinase inhibitor (TKI) treatment. Lantern Pharma is a clinical-stage precision oncology company that leverages artificial intelligence and machine learning through its proprietary RADR platform to transform cancer therapy development. The company's clinical pipeline also includes LP-184 (acylfulvene) and LP-284 (a TC-NER targeting compound in hematologic and solid tumors), as well as LP-184 for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
In addition to its therapeutic pipeline, Lantern Pharma has commercially launched Zeta.ai, a multi-agentic AI co-scientist platform available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. For more information, visit the company's newsroom at https://ibn.fm/LTRN.
The announcement underscores the potential for LP-300 to address an unmet medical need in never-smoker NSCLC patients, a population that often has distinct molecular characteristics and limited treatment options after TKI failure. The FDA's alignment on the protocol amendments may expedite the clinical development and regulatory review process, bringing a novel therapy closer to this patient group.
This development is part of Lantern Pharma's broader strategy to use AI-driven insights to identify patient populations most likely to benefit from its drug candidates, thereby increasing the efficiency and success rate of clinical trials. The company's focus on precision oncology aims to tailor treatments based on genetic and molecular profiles, potentially improving outcomes and reducing side effects compared to traditional chemotherapy.
Investors and stakeholders can access the full press release at https://ibn.fm/Rxklm. For more information about Lantern Pharma, visit their website. Note to investors: The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN.
